Anaeropharma Science, Inc. is a Japanese biopharmaceutical startup that was established in 2004 with a focus on developing innovative therapeutics to target hypoxic environments in solid cancers. The company's proprietary platform technology, recombinant bifidobacterium therapeutics, is at the core of its novel approach. Anaeropharma Science operates within the Biopharma, Biotechnology, Health and Wellness, and Pharmaceutical industries, positioning itself at the crossroads of cutting-edge research and healthcare innovation.
The company's most recent infusion of capital came in the form of a Venture Round investment on 01 January 2020. The backing for this round was provided by Mitsui Global Investment, signifying a strong vote of confidence in Anaeropharma Science's mission and potential.
Overall, Anaeropharma Science, Inc. has steadily built its presence and capabilities since its founding, carving out a unique position in the quest for more effective treatments in oncology. The recent investment from Mitsui Global Investment underscores the industry's recognition of the company's innovative approach and the potential impact of its developments on the field of cancer therapeutics.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Venture Round | Unknown | 1 |
|
01 Jan 2020 |
| Venture Round | $13.20M | 6 |
|
05 Jul 2017 |
| Venture Round | ¥2.20B | 1 |
|
21 Feb 2012 |
| Venture Round | ¥700.00M | 1 |
|
25 Nov 2010 |
| Seed Round | Unknown | 1 |
|
04 Apr 2007 |
No recent news or press coverage available for Anaeropharma Science, Inc..
We care about your data, and we'd love to use cookies make your experience better.
